GSK

Business Context and Reporting Period

Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended September 30, 2024
Overview: GSK reported Q3 2024 sales growth driven by Specialty Medicines, offsetting declines in Vaccines. The company confirmed its full-year 2024 guidance and declared a Q3 dividend of 15p per share. A significant one-time charge of £1.8 billion was recognized related to the Zantac litigation settlement.

Key Financial Metrics

Note: Growth percentages are at Constant Exchange Rates (CER) unless otherwise noted. Total results include a £1.8 billion Zantac settlement charge.

Material Changes vs. Prior Period

• Revenue Mix: Specialty Medicines sales grew 19% (CER) in Q3, driven by HIV (+12%), Oncology (+94%), and Respiratory/Immunology (+14%). Vaccines sales declined 15% (CER), primarily due to a 72% drop in Arexvy (RSV vaccine) and a 7% drop in Shingrix, attributed to ACIP guideline changes and COVID-19 prioritization in the US.
• Profitability Impact: Total Operating Profit and EPS collapsed due to a £1.8 billion ($2.3 billion) charge for the Zantac State Courts and Qui Tam settlements. Excluding this, Core Operating Profit grew 5% and Core EPS grew 5%.
• Cost Structure: Selling, General, and Administrative (SG&A) expenses surged 72% (CER) in Q3 due to the legal charge. Core SG&A remained disciplined, improving as a percentage of sales.
• Balance Sheet: Net debt decreased to £12.8 billion from £15.0 billion at year-end 2023, aided by free cash flow and proceeds from the disposal of Haleon shares.

Guidance, Outlook, and Risks

2024 Guidance (Confirmed)

GSK expects to deliver broadly around the middle of its existing ranges at Constant Exchange Rates (CER), excluding COVID-19 solutions:

• Turnover Growth: 7% to 9%
• Core Operating Profit Growth: 11% to 13%
• Core EPS Growth: 10% to 12%

Management Commentary

CEO Emma Walmsley highlighted strong growth in Specialty Medicines and progress in R&D, with 11 positive Phase III trials reported in 2024. The company resolved the vast majority of Zantac litigation to remove uncertainty. Five major new product launches are planned for 2025 (Blenrep, Depemokimab, Nucala for COPD, Gepotidacin, and MenABCWY).

Risks and Contingencies

• Legal: While 93% of Zantac state court cases were settled, approximately 6,000 cases remain pending, primarily in Delaware. GSK also faces ongoing patent litigation regarding RSV and mRNA technologies against Pfizer and Moderna.
• Regulatory: Vaccine sales are sensitive to ACIP guideline changes and government prioritization of other vaccines (e.g., COVID-19).
• Exchange Rates: A strengthening Sterling against the USD, Euro, and Yen is expected to negatively impact reported turnover and profit growth.

Investor Verification Checklist

• Zantac Settlement Finality: Verify the final approval status of the Qui Tam Settlement and the implementation timeline for the State Courts Settlement (expected H1 2025).
• Vaccine Demand Recovery: Monitor upcoming ACIP recommendations for Arexvy and Shingrix to assess if the Q3 decline is a temporary seasonal/regulatory anomaly or a structural shift.
• Core vs. Total Reconciliation: Review the reconciliation of Total to Core results to understand the magnitude of non-cash adjustments (amortization, contingent consideration remeasurements) impacting reported earnings.
• R&D Pipeline Milestones: Track regulatory decisions for key 2025 assets, specifically Depemokimab (asthma/CRSwNP) and Gepotidacin (UTI), which are critical to the growth outlook.
• Dividend Sustainability: Confirm the full-year dividend payout of 60p per share against the projected cash flow and capital allocation priorities.